BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Healthtrust Education - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Healthtrust Education
X-ORIGINAL-URL:https://education.healthtrustpg.com
X-WR-CALDESC:Events for Healthtrust Education
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190418
DTEND;VALUE=DATE:20190604
DTSTAMP:20260407T040617
CREATED:20190418T195638Z
LAST-MODIFIED:20190418T195758Z
UID:10001650-1555545600-1559606399@education.healthtrustpg.com
SUMMARY:HealthTrust Innovation Grant  |  June 3 deadline
DESCRIPTION:
URL:https://education.healthtrustpg.com/calendar/healthtrust-innovation-grant-june-3-deadline/
CATEGORIES:Cardiovascular,Central Service,Facilities,Food & Nutrition,Healthcare Executives,Lab,Nursing,Other,Pharmacy,Physicians,Radiology,Respiratory,Sterile Processing,Supply Chain,Sustainability
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20190531T113000
DTEND;TZID=UTC:20190531T123000
DTSTAMP:20260407T040617
CREATED:20190507T010307Z
LAST-MODIFIED:20190621T003519Z
UID:10001675-1559302200-1559305800@education.healthtrustpg.com
SUMMARY:"New Indications & Doses for Direct Oral Anticoagulants (DOACs)"
DESCRIPTION:Download a copy of this content. \nAccess the recording. \nHealthTrust presents…”New Indications & Doses for Direct Oral Anticoagulants (DOACs) \nSince the approval of direct oral anticoagulants (DOACs) for the prevention of stroke in patients with non-valvular atrial fibrillation and the prevention and treatment of venous thromboembolism (VTE)\, research has continued to delineate what other applications DOACs might have. Pharmacists may not be aware of updates to the indications\, doses and applications for these medications. Recently\, rivaroxaban has received FDA approval for two additional dose schedules and indications. Additionally\, new evidence has been published on the use of apixaban to prevent VTE in patients with cancer. The presenter will share information and evidence associated with these new indications. \nLearning Objectives for pharmacists  |  At the end of this session\, participants should be able to: \n\nDescribe the new applications and indications for apixaban and rivaroxaban\nEvaluate the evidence associated with each indication\nSelect a DOAC dose and schedule for a novel indication given a patient case\n\nLearning Objectives for pharmacy technicians  |  At the end of this session\, participants should be able to: \n\nList the new doses that are available for rivaroxaban and apixaban\nDetermine key dosing differences for rivaroxaban and apixaban\n\nPresenter: \n \nAlexandra Rain Ross\, PharmD  |  PGY-1 Pharmacy Resident  |  Memorial Hospital of South Bend \nTarget Audience: Pharmacists and Pharmacy Technicians \nContinuing Education Information: 1.0 contact hours approved for Pharmacists and Pharmacy Technicians. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Numbers for this activity are 0863-9999-19-044-L01-P and 0863-9999-19-044-L01-T . The activity will provide 1 hour (.1 CEUs) of continuing education credit to pharmacists and pharmacy technicians who attend the webinar and complete the online evaluation. \nNote about CE credit: If you plan to obtain credit\, stay until the end of the presentation to receive the verification code you will need to obtain your continuing education credit. A reminder that CE credit is individual. No group credit is available. Each person must register for this session and attend the webinar for 40 minutes or longer in order to receive an email after the event with instructions on how to apply for continuing education credit. Please do not share the code or forward the email you receive to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. Also\, please note: If you are joining only by phone\, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting. \nA participant\, sponsor\, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the Belmont COP may contact the Dean of Belmont University College of Pharmacy in writing at david.gregory@belmont.edu. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied\, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
URL:https://education.healthtrustpg.com/calendar/new-indications-doses-for-direct-oral-anticoagulants-doacs/
CATEGORIES:Hematology,Pharmacy
END:VEVENT
END:VCALENDAR